(Q30788761)

26 June 2017

title

Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug (English)

1 reference

26 June 2017

Prodrug Mono therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug (English)

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

pharmaceutical science

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

1

Frédéric Schmidt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713838

27 December 2023

author name string

Claude Monneret

series ordinal

2

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

26 June 2017

15 May 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12713838

full work available at URL

27 December 2023

https://api.elsevier.com/content/article/PII:S0968089603001081?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

https://api.elsevier.com/content/article/PII:S0968089603001081?httpAccept=text/plain

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

Bioorganic & Medicinal Chemistry

27 December 2023

published in

1 reference

26 June 2017

volume

11

1 reference

26 June 2017

issue

10

1 reference

26 June 2017

page(s)

2277-2283

1 reference

Drug targeting with monoclonal antibodies. A review

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Antibody directed enzymes revive anti-cancer prodrugs concept

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Discovery of podophyllotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Etoposide (VP-16-213). Current status of an active anticancer drug

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Etoposide: four decades of development of a topoisomerase II inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Etoposide. Current and future status

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Current status of etoposide in the management of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Etoposide: current status and future perspectives in the management of malignant neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Clinical and pharmacokinetic overview of parenteral etoposide phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Recent developments in the field of antitumour anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Synthesis, 470-MHz 1H NMR spectra, and activity of delactonized derivatives of the anticancer drug etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

Antitumor agents. II: Regio- and stereospecific syntheses of 1-beta-alkyl-1-desoxypodophyllotoxin derivatives and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900108-1

7 January 2021

3

47

3039

Jain

1987

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

8

58

1195

Bosslet

1998

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

9

57

2440

Mürdter

1997

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

Journal of the Chemical Society

27 December 2023

28

31

3224

Gensler

1966

1 reference

https://api.crossref.org/works/10.1016/S0968-0896(03)00108-1

27 December 2023

Identifiers

1 reference

release_bql2pzfokzhalnta6f2kgnofqi

26 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bql2pzfokzhalnta6f2kgnofqi

24 November 2022

mapped directly with Wikidata item

1 reference